Key Points
- ICON director Ciaran Murray sold 3,452 shares for about $710,000 at an average price of $205.66, reducing his reported direct holdings by 16.9% to 17,000 shares. The article gives no reason for the sale.
- ICON beat quarterly earnings and revenue estimates, reporting EPS of $2.66 versus $2.62 expected and revenue of $2.02 billion versus $2.01 billion; revenue was down 0.9% year over year.
- Analysts’ consensus rating was Moderate Buy, with an average price target of $213.76. Recent target increases included RBC’s move to $226 and Barclays’ move to $230.
Icon Plc (NASDAQ:ICLR - Get Free Report) Director Ciaran Murray sold 3,452 shares of the business's stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $205.66, for a total transaction of $709,938.32. Following the completion of the transaction, the director directly owned 17,000 shares in the company, valued at $3,496,220. This trade represents a 16.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Ciaran Murray also recently made the following trade(s):
- On Tuesday, August 11th, Ciaran Murray sold 2,677 shares of Icon stock. The shares were sold at an average price of $164.29, for a total transaction of $439,804.33.
Icon Price Performance
ICLR opened at $203.11 on Thursday. Icon Plc has a fifty-two week low of $66.57 and a fifty-two week high of $219.04. The firm has a 50-day moving average of $173.91 and a 200 day moving average of $146.83. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.32 and a current ratio of 1.32. The firm has a market cap of $15.55 billion, a P/E ratio of 34.96, a PEG ratio of 11.29 and a beta of 1.19.
Icon (NASDAQ:ICLR - Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.62 by $0.04. The business had revenue of $2.02 billion for the quarter, compared to analyst estimates of $2.01 billion. Icon had a net margin of 5.45% and a return on equity of 7.73%. The company's revenue for the quarter was down .9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.31 earnings per share. On average, research analysts expect that Icon Plc will post 9.71 EPS for the current year.
Institutional Trading of Icon
A number of institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. grew its stake in Icon by 10.3% in the 1st quarter. Principal Financial Group Inc. now owns 3,311,771 shares of the medical research company's stock valued at $366,481,000 after buying an additional 310,236 shares in the last quarter. Trinity Street Asset Management LLP raised its holdings in Icon by 27.1% during the 2nd quarter. Trinity Street Asset Management LLP now owns 1,535,462 shares of the medical research company's stock valued at $266,725,000 after acquiring an additional 327,314 shares during the period. Maple Rock Capital Partners Inc. lifted its position in shares of Icon by 257.8% during the second quarter. Maple Rock Capital Partners Inc. now owns 1,199,600 shares of the medical research company's stock worth $208,383,000 after acquiring an additional 864,300 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Icon by 50.8% during the first quarter. Dimensional Fund Advisors LP now owns 788,828 shares of the medical research company's stock worth $87,262,000 after acquiring an additional 265,858 shares in the last quarter. Finally, Sound Shore Management Inc. CT purchased a new stake in shares of Icon during the first quarter worth $69,379,000. 95.61% of the stock is currently owned by hedge funds and other institutional investors.
More Icon News
Here are the key news stories impacting Icon this week:
Analyst Ratings Changes
A number of equities research analysts recently commented on ICLR shares. Jefferies Financial Group reaffirmed a "buy" rating and issued a $254.00 price target on shares of Icon in a report on Thursday, October 29th. Royal Bank Of Canada increased their price objective on Icon from $185.00 to $226.00 and gave the company an "outperform" rating in a report on Thursday, October 29th. Citigroup increased their price objective on Icon from $175.00 to $215.00 and gave the company a "neutral" rating in a report on Thursday, October 29th. Barclays raised their target price on Icon from $175.00 to $230.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 29th. Finally, Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a $250.00 target price on shares of Icon in a research note on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Icon presently has a consensus rating of "Moderate Buy" and an average target price of $213.76.
Read Our Latest Stock Report on ICLR
About Icon
(
Get Free Report)
ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.
Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
